EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link: https://ebookbell.com/faq

We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.

For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Antifibrotic Drug Discovery Brenneman Jehrod Iyer Malliga R

Name: Antifibrotic Drug Discovery Brenneman Jehrod Iyer Malliga R
SKU: BELL-21986108
Price: 31.00 USD
Availability: InStock
Rating: 4.1 (60 reviews)

SKU: BELL-21986108

$ 31.00 ~~$ 45.00~~ (-31%)

4.1

60 reviews

Antifibrotic Drug Discovery Brenneman Jehrod Iyer Malliga R instant download after payment.

Publisher: Royal Society of Chemistry

File Extension: PDF

File size: 12.89 MB

Author: Brenneman, Jehrod; Iyer, Malliga R

ISBN: 9781788015103, 9781788015783, 178801510X, 1788015789

Language: English

Year: 2020

Product desciption

Antifibrotic Drug Discovery Brenneman Jehrod Iyer Malliga R by Brenneman, Jehrod; Iyer, Malliga R 9781788015103, 9781788015783, 178801510X, 1788015789 instant download after payment.

Anti-fibrotic Drug Discovery is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.;TGFß Signalling in Fibrosis; Targeting Integrins in Fibroproliferative Disease; Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor (FXR) Activators; Autotaxin Inhibitors in Fibrosis; Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology; Galectin-3 Involvement in Fibrotic Diseases; The Emerging Role of CXCR4 in IPF; BH3 Mimetic Drugs for Anti-Fibrotic Therapy; Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities; Targeting Fibroblasts in Cancer and Fibrosis